A Double-Blind, Controlled Phase 2 Study of the Safety and Efficacy of Modified Stem Cells (SB623) in Patients With Chronic Motor Deficit From Traumatic Brain Injury (TBI)

Trial Profile

A Double-Blind, Controlled Phase 2 Study of the Safety and Efficacy of Modified Stem Cells (SB623) in Patients With Chronic Motor Deficit From Traumatic Brain Injury (TBI)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 17 Sep 2017

At a glance

  • Drugs SB 623 (Primary)
  • Indications Brain injuries
  • Focus Therapeutic Use
  • Acronyms STEMTRA
  • Sponsors SanBio
  • Most Recent Events

    • 15 Aug 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Dec 2017.
    • 26 Oct 2016 According to a SanBio media release, first patient in Japan has been enrolled in this trial.
    • 21 Sep 2016 According to a SanBio media release, the trial has been initiated in Japan.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top